南京正泰电气有限公司

皇家凤仙集团是一家

该站点未添加描述description...

广东省产品认证服务协会

是一家国际性财富管理公司，专注于为境内外高净值客户提供财富管理、财富传承、慈善规划等家族传承综合性解决方案。致力于为客户提供全面精准的严选及判断，管控好风险，锚定未来趋势，帮助客户正确有序地实想法、达成目标，实现精神与财富共同成长、永续传承，缔造属于个人及家族的财富传奇。

天津中悦达科技有限公司是一家股份制企业，公司坐落在美丽的天津东丽开发区西侧，地理位置优越，距天津新港45Km，距火车站18Km，距空港9Km，交通十分便利。公司自成立之日起，即是一家以测量仪器生产为主的专业生产商，专业生产自动安平水准仪等测量仪器及其附件。

乐士集团

服务器托管价格，亦庄服务器托管，亦庄机房服务器托管价格，北京亦庄机柜租用，20A机柜租用，北京亦庄3KW机柜租用，

四川巴尔农牧集团有限公司是一家集房地产开发、超市连锁、酒店旅游、生物科技、农业种养(植)殖、农副产品加工为一体的多元化集团公司。

连云港市工业投资集团有限公司

该站点未添加描述description...

WestVacBiopharmaisfoundedbyAcademicianWeiYuquanfromWestChinaHospitalofSichuanUniversity,togetherwith10scientistsfromStateKeyLaboratoryofBiotherapy(SKLB).ItsheadquarterislocatedintheInternationalBio-Town,Chengdu.TheCEOofWestVacBiopharmaisProf.WeiYuquan,whoistheAcademicianofChineseAcademyofSciencesaswellastheDirectorofStateKeyLaboratoryofBiotherapy.WestVaciscommittedtoexploringthelatestbiotherapytechnologiesformajordiseases,includinginfectiousdiseases,malignanttumors,cardiovasculardiseases,andsoon.IthasattachedgreatimportanceintheResearchandDevelopment(R&D)ofCOVID-19vaccineespeciallyandbuildingaCOVID-19vaccineproductionplatform.StateKeyLaboratoryofBiotherapy(SKLB)wasestablishedbytheMinistryofSciencesandTechnologyofChinain2005andbecameoneoftheNationalR&DPlatformsforNovelDrugsfoundedbytheMinistriesofSciencesandTechnologyaswellasthatofHealthofChinain2008.ItisalsosupportedbyNationalCollaborativeInnovationProgramandhasbecometheNationalCollaborativeInnovationCenterforBiotherapysince2013.WestChinaHospitalofSichuanUniversity，foundedin1892,istheNationalCenterforDiagnosisandTreatmentofSevereandCriticalDiseasesinWesternChina.Itisalsotheworld’slargestcomprehensivehospitalcomplexlocatedinonecampusarea.RelyingonthemedicalresourcesofStateKeyLaboratoryofBiotherapyandWestChinaMedicalCenter,WestVachasadoptedrecombinantproteinmethodologytodeveloptheCOVID-19vaccine.Becauseofthesafetyoftheproteinvaccine,itisalsotheonlyCOVID-19vaccineapprovedfortheuseinchildrenover3yearsoldinChina.ThevaccinewasapprovedbytheNationalMedicalProductsAdministrationforclinicaltrialsonAugust21,2020.PhaseI/IIclinicaltrialshavebeencompleted,andphaseIIIclinicaltrialsarebeingcarriedoutinNepal,Kenya,Japanandothercountries.Thevaccinetargetsthespikeproteinbindingdomain(S-RBD)ofSARS-CoV-2,producingneutralizingantibodiestoblockCOVID-19infectionofhumancells.TheresultwaspublishedonNature,theworld’sfamousscientificjournalonJuly29th,2020.IthasalsobeenthefirstpaperofCOVIDvaccinepublishedbyNaturesincethepandemicoutbreak.TheS-RBDgeneoftheCOVID-19virusisintroducedintotheinsectcells,whichwereusedasafactorytoproducehigh-qualityrecombinantvaccineproteinandthendoesrefinedpurification.Suchtechnologyiseasytobemass-producedandbroughttothemarket.WestVacBiopharmaiscommittedtobecomingtheworld`sleadingvaccineandimmunotherapyplatform.